Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between, and including, +- 36-46 months of age at the time of vaccination.~* For primed subjects: having completed the full vaccination course with GSK1024850A in the primary study (NCT00307034).~* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.~* Written informed consent obtained from the parent(s)/guardian(s) of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to vaccination.~* For primed subjects: administration of any pneumococcal vaccine since the end of the primary study (NCT00307034).~* For unprimed subjects: previous vaccination with any pneumococcal vaccine.~* Administration of immunoglobulins and/or any blood products less than 6 months prior to the vaccination or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* History of reactions or allergic disease likely to be exacerbated by any component of the study vaccine.~* Acute disease at the time of enrolment.

- Gender: ALL
- Minimum Age: 36 Months
- Maximum Age: 46 Months
- Healthy Volunteers: t

Study Arms:
- Synflorix™ Group 1 (Type: EXPERIMENTAL): Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
- Synflorix™ Group 2 (Type: EXPERIMENTAL): Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
- Unprimed Group (Type: ACTIVE_COMPARATOR): Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).